HudsonAlpha, ORIEN Cancer Initiative Collaborate
News Sep 13, 2016
The Oncology Research Information Exchange Network® (ORIEN) and HudsonAlpha Institute for Biotechnology have announced a new collaboration to advance cancer research and care. Under the agreement, HudsonAlpha will provide genomic sequencing services for the ORIEN Avatar™ Research Program. The program allows the nation’s leading cancer centers to optimize and enable novel treatments and clinical trials, which could have the potential to impact millions of patients worldwide. Through the agreement, HudsonAlpha will provide DNA sequences for 20,000 patient samples, tumor and non-tumor, by 2019.
Their team will perform whole exome sequencing and RNA sequencing to learn more about the genetic makeup of cancerous tumors. The ORIEN Avatar Research Program is a first-of-its-kind collaboration that brings together patients, physicians, researchers and pharmaceutical companies to speed clinical development and discovery of treatments for advanced-stage cancers. It is an integral part of ORIEN, a national research partnership among 13 of the top cancer care institutions in the U.S. Together, ORIEN institutions have constructed the world’s largest cancer database, with more than 140,000 patients committing to lifetime study through ORIEN’s Total Cancer Care® Protocol.
By studying the patient—and not just the cancer—researchers can better understand the disease and how to best treat it. HudsonAlpha’s Genomic Service Laboratory will provide DNA sequencing services to identify the genetic disturbances and mutations of each patient’s cancer. Understanding the genetic makeup of a tumor, as well as the unique genetic profile of each patient can provide researchers at ORIEN member institutions and ORIEN Avatar pharmaceutical partners with valuable data to develop targeted therapies and launch new clinical trials.
“This unique program combines capabilities from leading cancer institutions across the United States in an effort to dramatically improve patient care and outcomes,” said Shawn Levy, PhD, director of the Genomic Services Laboratory. “We are honored to participate in this collaboration and look forward to helping make precision-based therapies a reality for more patients.” Health informatics solution company M2Gen is leading the ORIEN Avatar Research Program and says working with HudsonAlpha will help accelerate the discovery and delivery of personalized medicine.
“The ORIEN Avatar Research Program represents a collaborative space within the healthcare community to drive new discoveries and shorten clinical development timelines by proactively matching patients to trials. The sequencing capabilities and expertise of HudsonAlpha will help accelerate the process, creating more options for patients and a more effective means to drive the development of life-saving treatments,” said William S. Dalton, MD, PhD, founder and CEO of M2Gen, which manages ORIEN and the Total Cancer Care Protocol and database.
Herpesvirus and Alzheimer's Link: High abundance of Herpes genes in postmortem Alzheimer's brain tissueNews
Data from three different brain banks to suggest that human herpesviruses are more abundant in the brains of Alzheimer's patients and may play a role in regulatory genetic networks that are believed to lead to the disease.READ MORE
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Gene-edited Pigs are Resistant to Billion-dollar VirusNews
Scientists have produced pigs that can resist one of the world’s most costly animal diseases, by changing their genetic code. Tests with the virus – called Porcine Reproductive and Respiratory Syndrome, or PRRS – found the pigs do not become infected at all. The animals show no signs that the change in their DNA has had any other impact on their health or wellbeing.READ MORE